Martin Tammemagi

Research

Dr. Tammemagi is epidemiologist on the US National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. In the PLCO trial Dr. Tammemagi has and is leading a number of ancillary studies and he is full active member of the PLCO Lung Committee.

Dr. Tammemagi is epidemiologist on the US National Cancer Institute’s National Lung Screening Trial (NLST). He is full active member of the NLST Epidemiology and Health Services Research Working Group. Also, Dr. Tammemagi is Co-Chair of the NLST Joint Epidemiology Working Group, and he is leading several ancillary studies in the NLST.

Dr. Tammemagi is epidemiologist/analyst and co-investigator in the Pan -Canadian Early Detection of Lung Cancer Study.

Dr. Tammemagi is leading a study that is evaluating the impact of computed tomography chest screening on quality of life in the following study: Low-dose computed tomography for the early diagnosis of mesothelioma and lung cancer in prior asbestos workers.